Exagen (NASDAQ:XGN) is a health services company focused on transforming the care continuum for patients suffering from autoimmune diseases. By deploying a combination of unique testing services and proprietary technologies, Exagen aims to empower physicians with precise diagnostic, prognostic, and therapeutic solutions. The company is committed to advancing the field of autoimmune diagnostics through ongoing research and development projects, striving to uncover new insights and innovations that can improve patient outcomes. Exagen's principal objective is to enhance the quality of life for those affected by autoimmune conditions by providing accurate, early detection and facilitating targeted treatment strategies.